Novan Revenue and Competitors
Estimated Revenue & Valuation
- Novan's estimated annual revenue is currently $9.8M per year.
- Novan's estimated revenue per employee is $147,000
- Novan's total funding is $210.4M.
Employee Data
- Novan has 67 Employees.
- Novan grew their employee count by 20% last year.
Novan Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.1M | 21 | -5% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $67.1M | 288 | 1% | N/A | N/A |
#4 | $25.5M | 127 | 55% | N/A | N/A |
#5 | $69.6M | 264 | -2% | $35M | N/A |
#6 | $3.3M | 39 | 22% | N/A | N/A |
#7 | $3.1M | 33 | 3% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $35.9M | 136 | 15% | $637.8K | N/A |
#10 | $44M | 181 | -3% | N/A | N/A |
What Is Novan?
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate.
keywords:N/A$210.4M
Total Funding
67
Number of Employees
$9.8M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novan News
The event will spotlight Novan's newly acquired portfolio of commercial medical dermatology products and its proprietary nitric oxide-based...
Novan, Inc. is a specialty dermatology company focused on researching, developing and marketing innovative therapeutic products for skin...
Category: Behind the scenes. Company: Novan. Title: Chief Medical Officer. Birthplace: Kobe, Japan. Family: Husband, Taka, and two fluffy...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.2M | 67 | 10% | N/A |
#2 | $21.7M | 68 | -14% | N/A |
#3 | $12.5M | 69 | 0% | N/A |
#4 | $13.5M | 71 | 20% | $173.9M |
#5 | $25.1M | 72 | 16% | N/A |